Pasithea Therapeutics News

Express News | Pasithea Therapeutics Announces An Independent Safety Review Committee Completes Safety Review Of Data From First Dose Cohort In Phase 1 Trial Of PAS-004

BenzingaJun 13 07:07 ET

Express News | Pasithea Therapeutics Corp: Remain on Track to Present Our Initial Safety and Pharmacokinetic (Pk) Data in Q3 of 2024.

ReutersJun 13 06:59 ET

Express News | Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee (Src) Recommendation for Pas-004 in Ongoing Phase 1 Clinical Trial

ReutersJun 13 06:59 ET

12 Health Care Stocks Moving In Tuesday's Intraday Session

GainersConcord Medical Services (NYSE:CCM) shares moved upwards by 51.9% to $1.2 during Tuesday's regular session. The market value of their outstanding shares is at $52.1 million. Annexon (NASDAQ:ANN

BenzingaJun 4 12:31 ET

Express News | Pasithea Therapeutics To Present New Preclinical Data Showing PAS-004 Strongly Inhibiting NRAS Cancer Cell Lines

BenzingaMay 28 07:01 ET

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

Globe NewswireMay 28 06:59 ET

12 Health Care Stocks Moving In Friday's Intraday Session

GainersAkanda (NASDAQ:AKAN) shares increased by 103.8% to $0.27 during Friday's regular session. The company's market cap stands at $8.6 million. NovaBay Pharmaceuticals (AMEX:NBY) shares rose 48.66%

BenzingaMay 17 12:31 ET

10-Q: Quarterly report

SEC announcementMay 14 16:38 ET · Announcements

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing

GlobeNewswireApr 29 07:59 ET

Express News | Pasithea Therapeutics Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers

Moomoo 24/7Apr 24 07:59 ET

Pasithea Therapeutics Begins U.S. Trial for Cancer Treatment

InvestingFeb 13 08:04 ET

Pasithea Therapeutics Announces Opening Of Enrollment In The U.S. For Its Phase 1 Trial Of PAS-004

-- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy ---- Plans to open three additional sites in Eastern Europe

BenzingaFeb 13 07:59 ET

Top Premarket Decliners

VCI Global (VCIG) shares slumped more than 36% Friday premarket after the company priced a $2.8 million offering of stock and warrants. SEALSQ (LAES) shares tumbled 23%, a day after the company closed

MT NewswiresJan 12 07:43 ET

Pasithea Therapeutics Shares Rise on FDA Clearance to Evaluate PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics (KTTA) shares rose 12% in recent Tuesday trading after the company got US Federal Drug Administration clearance to assess PAS-004 in cancer patients with advanced solid tumors. P

MT NewswiresJan 2 15:16 ET

Pasithea Conducts 1-for-20 Reverse Stock Split, Gets FDA Okay for Study

Seeking AlphaJan 2 09:11 ET

Pasithea Therapeutics Shares Resume Trade

Pasithea Therapeutics Shares Resume Trade

BenzingaJan 2 09:00 ET

Express News | Pasithea Therapeutics Announces FDA Acceptance Of IND Application To Evaluate PAS-004 In Advanced Cancer Patients

Moomoo 24/7Jan 2 08:39 ET

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 – -- Initial readout

GlobeNewswireJan 2 08:35 ET

Pasithea Therapeutics To Carry Out 1-for-20 Reverse Stock Split On January 2nd, 2024

December 29th - $Pasithea Therapeutics(KTTA.US)$ is about to implement a 1-for-20 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from January 2nd, 2024.$Pasithe

moomoo NewsDec 28, 2023 19:55 ET

Press Release: Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023 SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics C

Dow JonesDec 28, 2023 17:00 ET